{
    "nct_id": "NCT06114745",
    "title": "A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of SHR-1707 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2025-07-09",
    "description_brief": "To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1707 in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD for 26 weeks.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "SHR-1707 (humanized anti\u2013amyloid-\u03b2 IgG1 monoclonal antibody; binds A\u03b2 fibrils and monomers, promotes A\u03b2 clearance)"
    ],
    "placebo": [
        "placebo (randomized, double-blind, placebo-controlled design)"
    ],
    "explanation_target": [
        "Reason: The investigational agent SHR-1707 is a humanized monoclonal antibody that binds amyloid-\u03b2 (A\u03b2) species (fibrils and monomers) and is being developed to reduce brain A\u03b2 deposition \u2014 i.e., it targets Alzheimer\u2019s pathology (amyloid). \ue200cite\ue202turn0search3\ue202turn0search4\ue201",
        "Act: The trial title and description state this is a Phase 1b randomized, double-blind, placebo-controlled multiple-dose study of SHR-1707 in patients with MCI due to AD and mild AD for 26 weeks, confirming the intervention and therapeutic intent (amyloid-targeting biologic). \ue200cite\ue202turn0search0\ue202turn0search5\ue201",
        "Reflect: Given SHR-1707 is a monoclonal antibody directed at A\u03b2 (a biologic targeting core AD pathology), it fits the definition of a \"disease-targeted biologic.\" It is not a small molecule, a general cognitive enhancer, nor an intervention aimed at neuropsychiatric symptoms. No meaningful ambiguity in category based on available descriptions. \ue200cite\ue202turn0search3\ue202turn0search5\ue201",
        "Web search results / sources (supporting evidence): 1) Phase 1b trial description and study design (Alzheimer's & Dementia). \ue200cite\ue202turn0search0\ue201 2) Phase 1 single-ascending-dose safety/PK/PD studies reporting SHR-1707 as an anti\u2011A\u03b2 IgG1 mAb (Alzheimer's Research & Therapy / PubMed / PMC). \ue200cite\ue202turn0search3\ue202turn0search4\ue201 3) ALZFORUM summary of SHR-1707 (mechanism and development status). \ue200cite\ue202turn0search5\ue201 4) Company (Jiangsu Hengrui) announcement about SHR-1707 Phase I enrollment/completion. \ue200cite\ue202turn0search7\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational agent SHR-1707 is described as a humanized anti\u2013amyloid-\u03b2 (A\u03b2) IgG1 monoclonal antibody that binds A\u03b2 fibrils and monomers and promotes A\u03b2 clearance\u2014i.e., it directly targets amyloid pathology in AD. \ue200cite\ue202turn0search3\ue202turn0search0\ue201",
        "Act: Extracted details \u2014 drug: SHR-1707 (humanized anti\u2011A\u03b2 IgG1 mAb; binds fibrils and monomers; developed to reduce brain A\u03b2 deposition). Based on this explicit amyloid\u2011\u03b2 mechanism, assign category 'A) Amyloid beta'. \ue200cite\ue202turn0search1\ue202turn0search3\ue201",
        "Reflect: The intervention is a disease\u2011targeted biologic aimed at a core AD pathology (A\u03b2). There is no indication of additional distinct therapeutic targets (e.g., tau, inflammation) or that the trial is non\u2011therapeutic, so 'A) Amyloid beta' is the most specific CADRO match. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Web search results / supporting evidence: 1) Phase 1b trial description noting SHR-1707 as a humanized anti\u2011A\u03b2 mAb and study design (Alzheimer's & Dementia). \ue200cite\ue202turn0search0\ue201 2) Phase 1 single\u2011ascending\u2011dose safety/PK/PD studies reporting SHR-1707 as an anti\u2011A\u03b2 IgG1 mAb that binds fibrils and monomers (Alzheimer's Research & Therapy). \ue200cite\ue202turn0search1\ue201 3) ALZFORUM summary of SHR-1707 (mechanism and development status). \ue200cite\ue202turn0search3\ue201"
    ]
}